issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures

materially cut down sales expenses from the previous year in alignment with the drop in sales revenue. Nevertheless, some of the sales expenses took time to adjust and did not fully reflect the slowdown in

adjust the assumptions for cash flows projections of those subsidiaries to calculate the recoverable amount appropriately, and to consider the adequacy and appropriateness of the impairment loss for

Administration (CFDA) at the beginning of 2 0 1 8 as the Company had to redesign its packaging to comply with the requirements of the license. Furthermore, the Company also found it necessary to adjust its sales

year to be in parallel with the plunge in sales revenue. Nevertheless, some of the sales expenses did not adjust promptly and did not fully mirror the slowdown in revenue as there is a lead time for

with the plunge in sales revenue. Nevertheless, some of the sales expenses did not adjust promptly and did not fully mirror the slowdown in revenue as there is a lead time for certain expenses that the

that the Company managed to properly slash sales expenses from the previous year to be in parallel with the plunge in sales revenue. Nevertheless, some of the sales expenses did not adjust promptly and

a new subsidiary 26/07/2022 18:29 Capital increase in a subsidiary 25/01/2022 19:07 Notification of the Investment in DP Survey and Law Co., Ltd. 25/01/2022 19:05 Notification of the Investment in

/2022 18:29 Capital increase in a subsidiary 25/01/2022 19:07 Notification of the Investment in DP Survey and Law Co., Ltd. 25/01/2022 19:05 Notification of the Investment in Amity Insurance Broker Co

and Machine Learning (ML) in business services, survey findings on providing international products to retail investors, insights on the growth of "finfluencers" in Thailand, support for Open Data use